As the Australian market reacts to global trends, with the ASX 200 showing signs of resilience despite recent fluctuations, investors are keenly observing opportunities that might arise. The term 'penny stock' may seem outdated, yet it remains relevant for those seeking growth potential in smaller or newer companies. By focusing on stocks with solid financial foundations, investors can uncover hidden value and potential stability within this niche segment.
Top 10 Penny Stocks In Australia
| Name | Share Price | Market Cap | Rewards & Risks |
| Dusk Group (ASX:DSK) | A$0.81 | A$50.44M | ✅ 4 ⚠️ 2 View Analysis > |
| IVE Group (ASX:IGL) | A$2.60 | A$402.03M | ✅ 4 ⚠️ 3 View Analysis > |
| MotorCycle Holdings (ASX:MTO) | A$3.38 | A$249.47M | ✅ 4 ⚠️ 2 View Analysis > |
| Pureprofile (ASX:PPL) | A$0.042 | A$49.13M | ✅ 3 ⚠️ 1 View Analysis > |
| Veris (ASX:VRS) | A$0.075 | A$38.83M | ✅ 4 ⚠️ 2 View Analysis > |
| West African Resources (ASX:WAF) | A$3.04 | A$3.47B | ✅ 4 ⚠️ 1 View Analysis > |
| Praemium (ASX:PPS) | A$0.765 | A$365.83M | ✅ 5 ⚠️ 2 View Analysis > |
| SKS Technologies Group (ASX:SKS) | A$3.27 | A$374.82M | ✅ 3 ⚠️ 1 View Analysis > |
| Service Stream (ASX:SSM) | A$2.38 | A$1.46B | ✅ 3 ⚠️ 1 View Analysis > |
| MaxiPARTS (ASX:MXI) | A$2.50 | A$138.61M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 440 stocks from our ASX Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Argenica Therapeutics (ASX:AGN)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Argenica Therapeutics Limited is an Australian biotechnology company focused on the research and development of neuroprotective therapeutic drugs, with a market cap of A$40.46 million.
Operations: Argenica Therapeutics generates revenue primarily from its research and development of medical device technology, amounting to A$3.21 million.
Market Cap: A$40.46M
Argenica Therapeutics, with a market cap of A$40.46 million, remains pre-revenue despite reporting A$3.73 million in revenue for the year ending June 30, 2025. The company is unprofitable with a net loss of A$7.17 million and has experienced increased volatility in its share price over the past year. While it has no debt and sufficient short-term assets to cover liabilities, its board lacks experience with an average tenure of 2.5 years. Recent developments include discussions on Phase 2 trial results for an acute ischaemic stroke treatment, highlighting ongoing research efforts amidst financial challenges.
- Click here and access our complete financial health analysis report to understand the dynamics of Argenica Therapeutics.
- Explore historical data to track Argenica Therapeutics' performance over time in our past results report.
IPD Group (ASX:IPG)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: IPD Group Limited is an Australian company that distributes electrical infrastructure, with a market cap of A$430.33 million.
Operations: The company's revenue is derived from two main segments: the Products Division, which generated A$334.53 million, and the Services Division, contributing A$20.16 million.
Market Cap: A$430.33M
IPD Group, with a market cap of A$430.33 million, has demonstrated solid financial performance with A$354.68 million in sales and net income of A$26.19 million for the year ended June 30, 2025. The company declared a fully franked dividend of 6.2 cents per share and maintains high-quality earnings despite a slight decline in profit margins from last year. IPD's short-term assets comfortably cover both its short- and long-term liabilities, while operating cash flow effectively covers debt obligations at 354.9%. However, its Return on Equity remains low at 16%, indicating room for improvement in shareholder returns.
- Get an in-depth perspective on IPD Group's performance by reading our balance sheet health report here.
- Review our growth performance report to gain insights into IPD Group's future.
United Overseas Australia (ASX:UOS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: United Overseas Australia Ltd, along with its subsidiaries, is involved in the development and resale of land and buildings across Malaysia, Singapore, Vietnam, and Australia, with a market cap of A$1.11 billion.
Operations: The company's revenue is primarily derived from its Land Development and Resale segment, which accounts for A$438.18 million.
Market Cap: A$1.11B
United Overseas Australia Ltd, with a market cap of A$1.11 billion, has shown steady financial performance in the real estate sector. The company reported net income of A$44.61 million for the half year ended June 30, 2025, reflecting earnings growth that surpasses its five-year average. Despite an unstable dividend track record, UOS's operating cash flow covers its debt well and short-term assets significantly exceed liabilities. With a seasoned management team and board of directors, UOS maintains high-quality earnings and adequate interest coverage but faces challenges with low return on equity at 5% and declining profit margins compared to last year.
- Jump into the full analysis health report here for a deeper understanding of United Overseas Australia.
- Examine United Overseas Australia's past performance report to understand how it has performed in prior years.
Where To Now?
- Click this link to deep-dive into the 440 companies within our ASX Penny Stocks screener.
- Want To Explore Some Alternatives? AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if United Overseas Australia might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com